Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC patients in small retrospective study

The incidence of metastatic bone disease or brain metastasis was not different between EGFR mutated, KRAS mutated and KRAS/EGFR wild type patients in small, retrospective study performed by Dutch investigators. Time from diagnosis of metastatic non-small cell lung cancer to development of metastatic bone disease, first skeletal-related event or brain metastasis and post-brain metastasis survival did not differ. However, survival after diagnosis of metastatic bone disease was longer in EGFR mutated patients. The results were presented by Dr Lizza Hendriks of the Department of Respiratory Medicine, Maastricht University Medical Centre in Maastricht, Netherlands at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), held 9-11 May, 2013 in Lugano, Switzerland. Read more here.